Virtus Investment Advisers LLC Has $76,000 Holdings in REGENXBIO Inc. $RGNX

Virtus Investment Advisers LLC trimmed its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 51.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,219 shares of the biotechnology company’s stock after selling 9,611 shares during the period. Virtus Investment Advisers LLC’s holdings in REGENXBIO were worth $76,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of REGENXBIO by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock worth $24,832,000 after acquiring an additional 487,036 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of REGENXBIO by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,128,521 shares of the biotechnology company’s stock worth $9,267,000 after buying an additional 21,575 shares in the last quarter. 22NW LP acquired a new stake in shares of REGENXBIO during the 1st quarter worth approximately $4,781,000. AQR Capital Management LLC increased its stake in shares of REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after acquiring an additional 594,161 shares in the last quarter. Finally, Trexquant Investment LP increased its stake in shares of REGENXBIO by 205.6% in the 1st quarter. Trexquant Investment LP now owns 458,538 shares of the biotechnology company’s stock valued at $3,279,000 after acquiring an additional 308,516 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Insider Buying and Selling at REGENXBIO

In other news, CEO Curran Simpson sold 20,811 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares in the company, valued at approximately $2,727,964.44. This represents a 8.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 36,169 shares of company stock valued at $416,598. Insiders own 12.79% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on RGNX. Barclays cut their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Wall Street Zen raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Monday, November 24th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, November 20th. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of REGENXBIO in a report on Tuesday, October 7th. Finally, Royal Bank Of Canada upped their price target on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, REGENXBIO currently has an average rating of “Moderate Buy” and an average target price of $28.63.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $13.34 on Monday. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $13.93. The company has a market capitalization of $675.27 million, a price-to-earnings ratio of -3.84 and a beta of 1.14. The company’s 50-day moving average is $11.55 and its 200 day moving average is $9.84.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.18. The company had revenue of $29.73 million for the quarter, compared to analysts’ expectations of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. As a group, research analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.